Scutellarin therapy of T2DM mice at doses of 10 or 20 mg/kg body weight significantly reduced indices of metabolic, lipidemic, and cardiac functioning, according to Huo et al. (65) Additionally, scutellarin reduced inflammation, apoptosis, and oxidative stress in the T2DM heart through activating the Nrf2/Keap1/ARE pathway and suppressing the mitochondrial apoptotic pathway and the TLR/MYD88/NF-κB pathway. Here, KEAP1 is linked to type 2 diabetes mellitus.